Publicació científica

S'han trobat 1317 publicacions amb els criteris indicats.
Peña M, Serra J, Ribera JM

Cardiac arrest in a patient diagnosed with acute myeloid leukemia after the first dose of idarubicin.

Med Clin (Barc) 3 Mai 2018, . Epub 3 Mai 2018Més informació
Torrent A, Ferrá C, Ribera JM

Graft-versus-host disease after an infection by Rickettsia conorii induced by a tick's bite.

Med Clin (Barc) 2 Mai 2018, . Epub 2 Mai 2018Més informació
Ribera JM, García O, Gil C, Mercadal S, García-Cadenas I, Montesinos P, Barba P, Vives S, González-Campos J, Tormo M, Esteve J, López A, Moreno MJ, Ribera J, Alonso N, Bermúdez A, Amigo ML, Genescà E, García D, Vall-Llovera F, Bergua JM, Guàrdia R, Monteserín MC, Bernal T, Calbacho M, Martínez MP, Feliu E

Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia.

Leuk. Res. Mai 2018, 68 79-84. Epub 19 Mar 2018
The standardization of treatment of older adults with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) is challenging, especially in the age range of 55-65 years. This study aimed to compare intensive, pediatric-inspired therapy with non-intensive therapy in this population of patients.
Més informació
Misiewicz-Krzeminska I, Corchete LA, Rojas EA, Martínez-López J, García-Sanz R, Oriol A, Bladé J, Lahuerta JJ, Miguel JS, Mateos MV, Gutiérrez NC

A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.

Haematologica Mai 2018, 103 (5) 880-889. Epub 15 Mar 2018
Protein analysis in bone marrow samples from patients with multiple myeloma has been limited by the low concentration of proteins obtained after CD138
Més informació
Wierzbowska A, Wawrzyniak E, Pluta A, Robak T, Mazur GJ, Dmoszynska A, Cermak J, Oriol A, Lysak D, Arthur C, Doyle M, Xiu L, Ravandi F, Kantarjian HM

Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial.

Am. J. Hematol. Mai 2018, 93 (5) E125-E127. Epub 24 Feb 2018Més informació
Sorigue M, Sarrate E, Orna E

Importance of dosing direct oral anticoagulants appropriately.

Med Clin (Barc) 20 Abr 2018, . Epub 20 Abr 2018Més informació
Cabezón M, Bargay J, Xicoy B, García O, Borrás J, Tormo M, Marcé S, Pedro C, Valcárcel D, Jiménez MJ, Guàrdia R, Palomo L, Brunet S, Vall-Llovera F, Garcia A, Feliu E, Zamora L

Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine.

Oncotarget 10 Abr 2018, 9 (27) 19342-19355. Epub 10 Abr 2018
Myelodysplastic syndromes (MDS) are stem cell disorders caused by various gene abnormalities. We performed targeted deep sequencing in 39 patients with high-risk MDS and secondary acute myeloid leukemia (sAML) at diagnosis and follow-up (response and/or relapse), with the aim to define their mutational status, to establish if specific mutations are biomarkers of response to 5-azacytidine (AZA) and/or may have impact on survival. Overall, 95% of patients harbored at least one mutation.
Més informació
Tejedor JR, Bueno C, Cobo I, Bayón GF, Prieto C, Mangas C, Pérez RF, Santamarina P, Urdinguio RG, Menéndez P, Fraga MF, Fernández AF

Epigenome-wide analysis reveals specific DNA hypermethylation of T cells during human hematopoietic differentiation.

Epigenomics 5 Abr 2018, . Epub 5 Abr 2018
Epigenetic regulation plays an important role in cellular development and differentiation. A detailed map of the DNA methylation dynamics that occur during cell differentiation would contribute to decipher the molecular networks governing cell fate commitment.
Més informació
Sorigue M, Mercadal S, Alonso S, Fernández-Álvarez R, Sancho JM

Is there a role for the international prognostic index in follicular lymphoma?

Ann. Hematol. Abr 2018, 97 (4) 713-715. Epub 13 Des 2017Més informació
Arana P, Paiva B, Cedena MT, Puig N, Cordon L, Vidriales MB, Gutierrez NC, Chiodi F, Burgos L, Anglada LL, Martinez-Lopez J, Hernandez MT, Teruel AI, Gironella M, Echeveste MA, Rosiñol L, Martinez R, Oriol A, De la Rubia J, Orfao A, Blade J, Lahuerta JJ, Mateos MV, San Miguel JF

Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials.

Leukemia Abr 2018, 32 (4) 971-978. Epub 3 Nov 2017
Persistence of minimal residual disease (MRD) after treatment for myeloma predicts inferior outcomes, but within MRD-positive patients there is great heterogeneity with both early and very late relapses. Among different MRD techniques, flow cytometry provides additional information about antigen expression on tumor cells, which could potentially contribute to stratify MRD-positive patients. We investigated the prognostic value of those antigens required to monitor MRD in 1265 newly diagnosed patients enrolled in the GEM2000, GEM2005MENOS65, GEM2005MAS65 and GEM2010MAS65 protocols. Overall, CD19
Més informació